Insider buying last 90 days
No open-market insider purchases were filed for CRSP in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CRSP insider filing, plotted on the chart in Gekko.Open CRSP in Gekko
NASDAQ: CRSP
CRISPR Therapeutics (CRSP) Stock Analysis & Forecast
Sep 28 close
$54.09−0.14 (−0.3%)
Gekko Brief
AI summaryCRISPR Therapeutics draws attention this week on continued commentary around Casgevy, its gene-editing cell therapy, which saw a 78% sequential sales increase in the second quarter, reinforcing its commercial trajectory even as newer AI-driven gene editing approaches are flagged as a longer-term competitive risk. Citizens reaffirmed its Market Outperform rating and $80 price target, pointing to Casgevy's commercialization and a late-stage pipeline in cardiovascular and metabolic indications. A Form 144 filing was also noted this week, alongside a disclosed options exercise and sale by the company's General Counsel.
CRSP closed at $54.09, down 0.3%, sitting above both its 50-day average of $53.73 and its 200-day average of $53.32. The GekkoIndex reads 60.1, placing the stock in the Accumulation zone. Shares trade 19.3% below the Gekko Fair Value estimate of $66.99. Over the past month the stock is down 8.9%, and over six months up 18.2%.
The next earnings report is set for 9 November 2026, 41 days out, beyond a typical 20-trading-day holding window; the prior report on 3 August showed a loss of $0.94 per share against a $1.19 estimate, with a 10.6% reaction. In the last 30 days there has been 1 unusual options signal, with call premium of $245,610 against put premium of $41,810. Seasonality over the next 20 trading days has averaged -9.2% across 5 years, rising in 2 of them. Analyst consensus target stands at $87.56 across 13 firms, with 8 buy and 5 hold ratings.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
CRISPR Therapeutics price vs fair value
Close $54.09200-day averageGekko Fair Value $66.99
CRISPR Therapeutics quick facts
- Market cap
- $5.22B
- P/E ratio
- —
- Forward P/E
- 23.4
- EPS, TTM
- −$4.71
- Revenue, TTM
- $13.39M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.76
- Volume
- 1.27M avg 1.59M
- 1-year return
- −10.3%
- Typical daily move
- ±5.4%
- Typical 20-day move
- ±10.8%
- 50-day average
- $53.73
- 200-day average
- $53.32
- Next earnings
- Nov 9
- Shares outstanding
- 96.69M
CRISPR Therapeutics swing-trade checklist
CRISPR Therapeutics scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive0 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $54.09 is above the 50-day ($53.73) and 200-day ($53.32) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexsupportive
60.1, Accumulation
Reading 60.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
19.3% below
Price is 19.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 41 days
Next report Nov 9, 2026, 41 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−9.2% on average
From this point in the calendar, the next 20 trading days averaged −9.2% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
CRISPR Therapeutics stock chart and price history
CRISPR Therapeutics closed at $54.09 on Sep 28, 2026, −10.3% over the past year, inside a 52-week range of $44.12 to $78.48.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −8.9%
- 3 months
- −4.0%
- 6 months
- +18.2%
- 1 year
- −10.3%
The full CRSP chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CRSP in Gekko
Follow CRISPR Therapeutics through every session
Put CRSP on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CRSP in GekkoFree for 7 days. No credit card required.
About CRISPR Therapeutics
CRISPR Therapeutics works on gene-editing treatments for serious illnesses, built around its CRISPR/Cas9 technology, which allows targeted changes to genetic material. Its research spans blood disorders, cancer, regenerative medicine and rare diseases, and it is best known for CTX001, a gene-edited therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease that works by editing a patient's own stem cells to raise fetal hemoglobin levels.
Beyond CTX001, the company is developing donor-derived CAR-T candidates such as CTX110, CTX120 and CTX130, aimed at different blood cancers and solid tumors, along with VCTX210, a stem cell-based candidate for type 1 diabetes, and additional in vivo editing programs targeting the liver, lungs, muscles and nervous system. It carries out this work partly through partnerships, including ones with Bayer Healthcare, Vertex Pharmaceuticals, ViaCyte, Nkarta and Capsida Biotherapeutics.
CRISPR Therapeutics was founded in 2013 and is headquartered in Zug, Switzerland. Its shares are listed on the NASDAQ under the ticker CRSP.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- crisprtx.com
CRISPR Therapeutics GekkoIndex: the smart money zone
CRISPR Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.1, in the Accumulation zone, up 6.6 points over five sessions.
60.1Accumulation
Up 6.6 points over five sessions, from the Neutral zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 37 | +0.2% | +3.4% | ||
| Accumulation (current zone) | 256 | +1.5% | +3.7% | ||
| Neutral | 330 | −0.7% | −2.1% | ||
| Distribution | 47 | +0.4% | 0.0% | ||
| Selling | 2 | Too few readings yet | |||
Average CRSP share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the CRSP price, zone by zone.Track CRSP in Gekko
Is CRISPR Therapeutics stock overvalued? Gekko Fair Value
CRISPR Therapeutics trades 19.3% below Gekko Fair Value of $66.99, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what CRISPR Therapeutics shares are worth, recalculated every trading day.
$66.99
Gekko Fair Value, Sep 29, 2026
19.3% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CRSP in Gekko
CRISPR Therapeutics insider and Congress trading
No open-market insider purchases were filed for CRISPR Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CRSP were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CRSP, plotted on the chart in Gekko.Open CRSP in Gekko
Buybacks
CRISPR Therapeutics has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $722K
- As a share of market cap
- 0.01%
From company filings.
Unusual options activity last 30 days
1signal, 85% of the flagged premium in calls.
Latest: Bullish flow on Sep 18, $287K in unusual premium.
Every signal with its contract, strike and premium.Unlock in Gekko
CRISPR Therapeutics earnings: next date and track record
CRISPR Therapeutics reports on Nov 9, 2026 (41 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 9, 2026
41 days away
- EPS estimate
- −$1.06
- Revenue estimate
- $14.62M
4 of 8reports beat the EPS estimate
±5.8%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | −$0.94 est −$1.19 | $10.18M est $7.45M | +10.6% |
| May 4, 2026 | −$1.28 est −$1.23 | $1.46M est $6.06M | +1.5% |
| Feb 12, 2026 | −$1.37 est −$1.17 | $864K est $4.72M | +9.8% |
| Nov 10, 2025 | −$1.17 est −$1.31 | $889K est $9.12M | +0.2% |
| Aug 5, 2025 | −$2.40 est −$1.47 | $892K est $6.14M | −5.5% |
| May 6, 2025 | −$1.58 est −$1.27 | $865K est $5.96M | −9.0% |
| Feb 11, 2025 | −$0.44 est −$1.19 | $35.00M est $8.06M | +9.9% |
| Nov 5, 2024 | −$1.01 est −$1.40 | $602K est $7.70M | +0.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
CRISPR Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for CRISPR Therapeutics is $87.56, +61.9% from the last close, from 13 firms rating the stock in the last 90 days.
$87.56consensus 12-month target, +61.9% from the last close
Now $54.09Avg $87.56
Low $45High $110
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 4 | Citi | $88 | +62.7% |
| Aug 31 | H.C. Wainwright | $80 | +47.9% |
| Aug 31 | Evercore ISI | $76 | +40.5% |
| Aug 31 | Needham | $82 | +51.6% |
| Aug 28 | Morgan Stanley | $60 | +10.9% |
+3.7%average 20-day move after past Accumulation readings
−9.2%average move over the next 20 trading days in the last 5 years
±5.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
CRISPR Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, CRISPR Therapeutics averaged −9.2% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.1% | 2 of 5 |
| Next 10 trading days | −3.7% | 1 of 5 |
| Next 15 trading days | −5.3% | 2 of 5 |
| Next 20 trading days | −9.2% | 2 of 5 |
| Next 30 trading days | −5.3% | 2 of 5 |
For scale, CRSP’s typical 20-trading-day move in either direction is about 10.8%.
CRISPR Therapeutics market cap and key statistics
CRISPR Therapeutics’s market cap is $5.22B and revenue of $13.39M over the last twelve months.
Valuation
- Market cap
- $5.22B
- Forward P/E
- 23.4
- EPS, TTM
- −$4.71
- Gekko Fair Value
- $66.99
Trading
- Volume
- 1.27M
- Avg volume, 20 days
- 1.59M
- 52-week high
- $78.48
- 52-week low
- $44.12
- Shares outstanding
- 96.69M
Financials
- Revenue, TTM
- $13.39M
- Profit margin
- 0%
- Return on equity
- -26.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.76
- Typical daily move
- ±5.4%
- Typical 20-day move
- ±10.8%
CRISPR Therapeutics stock news this week
Coverage of CRISPR Therapeutics this week reads neutral: 5 positive, 7 neutral and 1 negative headlines.
- CRISPR Therapeutics stock price target reaffirmed at $80 by CitizensInvesting.com, Sep 28
- CRISPR Therapeutics (NASDAQ:CRSP) & Septerna (NASDAQ:SEPN) Head-To-Head SurveyDefense World, Sep 28
- Form 144 CRISPR THERAPEUTICS AG For: 27 September By Investing.comInvesting.com UK, Sep 27
- CRISPR Therapeutics (NASDAQ:CRSP) Stock: Insider James Kasinger Sells 10,400 SharesDefense World, Sep 26
- CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's WhyZacks Investment Research, Sep 25
- CRISPR Therapeutics (CRSP) counsel exercised options and sold 10,400 shares under a trading plan.Stock Titan, Sep 25
CRISPR Therapeutics peers
CRISPR Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
CRISPR Therapeutics stock FAQ
What is CRISPR Therapeutics’s market cap?
CRISPR Therapeutics’s market cap is $5.22B at the Sep 28, 2026 close of $54.09, with 96.69M shares outstanding.
What is the CRISPR Therapeutics stock forecast?
The consensus analyst 12-month price target for CRISPR Therapeutics is $87.56, +61.9% from the last close. Of the 13 firms that rated the stock in the last 90 days, 8 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is CRISPR Therapeutics stock overvalued or undervalued?
On Gekko’s estimate CRISPR Therapeutics is undervalued: the Sep 28, 2026 close of $54.09 is 19.3% below Gekko Fair Value of $66.99. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does CRISPR Therapeutics report earnings next?
CRISPR Therapeutics is expected to report on Nov 9, 2026 (41 days away). Analysts expect earnings of −$1.06 per share on revenue of $14.62M. CRISPR Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 5.8% on average across the report.
What is CRISPR Therapeutics’s 52-week high and low?
CRISPR Therapeutics’s 52-week high is $78.48 and its 52-week low is $44.12; it closed at $54.09 on Sep 28, 2026, −10.3% over the past year. Over the last five years the shares peaked at $115.78 on Sep 28, 2021.
Is CRISPR Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, gekkoindex, fair value, smart money and earnings risk) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in CRISPR Therapeutics?
Gekko flagged 1 unusual options signal in CRISPR Therapeutics over the last 30 days, with $246K of flagged premium in calls and $42K in puts. The latest, bullish flow, was on Sep 18, 2026 with $287K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See CRISPR Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.